Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.

Larsen JR, Vedtofte L, Jakobsen MSL, Jespersen HR, Jakobsen MI, Svensson CK, Koyuncu K, Schjerning O, Oturai PS, Kjaer A, Nielsen J, Holst JJ and 4 more

Show all authors

Ekstrøm CT, Correll CU, Vilsbøll T, Fink-Jensen A

JAMA psychiatry1 Jul 2017Cited by 174 (Europe PMC)

PMID28601891PMCIDPMC5710254DOI10.1001/jamapsychiatry.2017.1220PepBankPUB-28601891

Source link PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In overweight or obese patients with prediabetes and schizophrenia spectrum disorder on clozapine or olanzapine, glucose tolerance improved with liraglutide compared with placebo.
In plain wordsIn patients with schizophrenia and prediabetes on clozapine or olanzapine, liraglutide improved glucose tolerance more than placebo.
Peptide
Liraglutide
Outcome
IncreaseGlucose tolerance on 75-g oral glucose tolerance test
Study
n = 97
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Glucose tolerance improved in the liraglutide group compared with the placebo group (P < .001).
2 context sentences(design, population, supporting numbers)
Summary · context
The primary end point was change in glucose tolerance estimated by a 75-g oral glucose tolerance test result.
Summary · context
Participants received stable treatment with clozapine or olanzapine, were overweight or obese, and had prediabetes.
Report a problemFND-2860189101
02HumanRandomized controlled trialEfficacy outcome
In patients with schizophrenia spectrum disorder on clozapine or olanzapine, body weight decreased with liraglutide by 5.3 kg compared with placebo.
In plain wordsIn patients with schizophrenia on clozapine or olanzapine, liraglutide led to more weight loss than placebo.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n = 97
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 16 weeksAs given in this study (human).
Measurements
Body weight difference
5.3 kg
liraglutide vs placebo
Source sentences
Summary
Body weight decreased with liraglutide compared with placebo (-5.3 kg; 95% CI, -7.0 to -3.7 kg).
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary end points included change in body weight and cardiometabolic parameters.
Summary · context
Participants received stable treatment with clozapine or olanzapine, were overweight or obese, and had prediabetes.
Report a problemFND-2860189103
03HumanRandomized controlled trialEfficacy outcome
In patients with schizophrenia spectrum disorder on clozapine or olanzapine, waist circumference fell by 4.1 cm more with liraglutide than with placebo.
In plain wordsIn patients with schizophrenia on clozapine or olanzapine, liraglutide reduced waist size more than placebo.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference change
Study
n = 97
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Reductions in waist circumference (-4.1 cm; 95% CI, -6.0 to -2.3 cm), systolic blood pressure (-4.9 mm Hg; 95% CI, -9.5 to -0.3 mm Hg), visceral fat (-250.19 g; 95% CI, -459.9 to -40.5 g), and low-density lipoprotein levels (-15.4 mg/dL; 95% CI, -23.2 to -7.7 mg/dL) occurred with liraglutide compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary end points included change in body weight and cardiometabolic parameters.
Summary · context
Participants received stable treatment with clozapine or olanzapine, were overweight or obese, and had prediabetes.
Report a problemFND-2860189104
04HumanRandomized controlled trialEfficacy outcome
In patients with schizophrenia spectrum disorder on clozapine or olanzapine, systolic blood pressure fell by 4.9 mm Hg more with liraglutide than with placebo.
In plain wordsIn patients with schizophrenia on clozapine or olanzapine, liraglutide lowered systolic blood pressure more than placebo.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure change
Study
n = 97
Comparator
Placebo
Analysis
Secondary
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Reductions in waist circumference (-4.1 cm; 95% CI, -6.0 to -2.3 cm), systolic blood pressure (-4.9 mm Hg; 95% CI, -9.5 to -0.3 mm Hg), visceral fat (-250.19 g; 95% CI, -459.9 to -40.5 g), and low-density lipoprotein levels (-15.4 mg/dL; 95% CI, -23.2 to -7.7 mg/dL) occurred with liraglutide compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary end points included change in body weight and cardiometabolic parameters.
Summary · context
Participants received stable treatment with clozapine or olanzapine, were overweight or obese, and had prediabetes.
Report a problemFND-2860189105
05HumanRandomized controlled trialEfficacy outcome
In patients with schizophrenia spectrum disorder on clozapine or olanzapine, visceral fat fell by 250.19 g more with liraglutide than with placebo.
In plain wordsIn patients with schizophrenia on clozapine or olanzapine, liraglutide reduced belly (visceral) fat more than placebo.
Peptide
Liraglutide
Outcome
DecreaseVisceral fat change
Study
n = 97
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Reductions in waist circumference (-4.1 cm; 95% CI, -6.0 to -2.3 cm), systolic blood pressure (-4.9 mm Hg; 95% CI, -9.5 to -0.3 mm Hg), visceral fat (-250.19 g; 95% CI, -459.9 to -40.5 g), and low-density lipoprotein levels (-15.4 mg/dL; 95% CI, -23.2 to -7.7 mg/dL) occurred with liraglutide compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary end points included change in body weight and cardiometabolic parameters.
Summary · context
Participants received stable treatment with clozapine or olanzapine, were overweight or obese, and had prediabetes.
Report a problemFND-2860189106
06HumanRandomized controlled trialEfficacy outcome
In patients with schizophrenia spectrum disorder on clozapine or olanzapine, low-density lipoprotein levels fell by 15.4 mg/dL more with liraglutide than with placebo.
In plain wordsIn patients with schizophrenia on clozapine or olanzapine, liraglutide lowered LDL cholesterol more than placebo.
Peptide
Liraglutide
Outcome
DecreaseLDL cholesterol change
Study
n = 97
Comparator
Placebo
Analysis
Secondary
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Reductions in waist circumference (-4.1 cm; 95% CI, -6.0 to -2.3 cm), systolic blood pressure (-4.9 mm Hg; 95% CI, -9.5 to -0.3 mm Hg), visceral fat (-250.19 g; 95% CI, -459.9 to -40.5 g), and low-density lipoprotein levels (-15.4 mg/dL; 95% CI, -23.2 to -7.7 mg/dL) occurred with liraglutide compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Secondary end points included change in body weight and cardiometabolic parameters.
Summary · context
Participants received stable treatment with clozapine or olanzapine, were overweight or obese, and had prediabetes.
Report a problemFND-2860189107
07HumanRandomized controlled trialEfficacy outcome
In patients with schizophrenia spectrum disorder on clozapine or olanzapine, 63.8% of liraglutide-treated participants developed normal glucose tolerance versus 16.0% with placebo.
In plain wordsIn patients with schizophrenia on clozapine or olanzapine, more people reached normal glucose tolerance with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
IncreaseNormal glucose tolerance achieved
Study
n = 97
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 16 weeksAs given in this study (human).
Measurements
Normal glucose tolerance
63.8%
liraglutide
Normal glucose tolerance
16%
placebo
Source sentences
Summary
Altogether, 30 liraglutide-treated participants (63.8%) developed normal glucose tolerance compared with 8 placebo-treated participants (16.0%) (P < .001; number needed to treat, 2).
1 context sentence(design, population, supporting numbers)
Summary · context
Participants received stable treatment with clozapine or olanzapine, were overweight or obese, and had prediabetes.
Report a problemFND-2860189102
08HumanRandomized controlled trialSafety outcome
In patients with schizophrenia spectrum disorder on clozapine or olanzapine, adverse events with liraglutide affected mainly the gastrointestinal tract.
In plain wordsIn patients with schizophrenia on clozapine or olanzapine, side effects of liraglutide were mainly in the digestive tract.
Peptide
Liraglutide
Outcome
Not applicableAdverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Adverse events with liraglutide affected mainly the gastrointestinal tract.
1 context sentence(design, population, supporting numbers)
Summary · context
Participants received stable treatment with clozapine or olanzapine, were overweight or obese, and had prediabetes.
Report a problemFND-2860189108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 2NCT01845259

Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?

Psychiatric Centre Rigshospitaletn = 103Apr 2013 to est. Mar 2017

Impaired Glucose Tolerance Associated With Drugs

Trial page ClinicalTrials.govUpdated 5 May 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.